digraph structs {
rankdir=LR;
g0 [shape=record,label="http://dikb.org/precipita\lnt-drug/bd13b90c-d25b-451\l6-8c8a-521df5e08b52\l\l\<obo:RxNorm_31565\>\l|label\lrdfs:label\lnefazodone\l",color=blue]
g1 [shape=record,label="http://purl.obolibrary.or\lg/obo/UO_0000187\l\lrdfs:Class\l",color=blue]
g2 [shape=record,label="http://purl.obolibrary.or\lg/obo/PATO_0000125\l\lrdfs:Class\l",color=blue]
g3 [shape=record,label="http://dikb.org/method/85\l81039c-8447-464f-a3cf-d78\la091df622\l\lobo:DIDEO_00000124\l|label\lrdfs:label\ldivalproex sodium-INVEGA \lDDI clinical trial\l",color=blue]
g4 [shape=record,label="http://purl.obolibrary.or\lg/obo/UO_0000022\l\lrdfs:Class\l",color=blue]
g5 [shape=record,label="http://dikb.org/precipita\lnt-value-measurement-datu\lm/3fa89768-6b7c-4e1b-9ef2\l-f555271f6cc2\l\lobo:IAO_0000109\l",color=blue]
g5 -> g73 [label="has specified value\lobo:OBI_0001937\l"]
g5 -> g9 [label="\lobo:IAO_0000221\l"]
g6 [shape=record,label="http://purl.obolibrary.or\lg/obo/RO_0000053\l\lrdf:Property\l",color=blue]
g7 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000576\l\lrdfs:Class\l",color=blue]
g8 [shape=record,label="http://dikb.org/object-va\llue-specification/0b17c4e\lc-0e33-470c-892e-9ea4265a\l414a\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l.2\l",color=blue]
g8 -> g31 [label="\lobo:IAO_0000039\l"]
g9 [shape=record,label="http://dikb.org/precipita\lnt-mass/622eeb38-d5dc-4eb\la-9fa0-2f11f959e28f\l\lobo:PATO_0000125\l",color=blue]
g10 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000039\l\lrdf:Property\l",color=blue]
g11 [shape=record,label="http://dikb.org/precipita\lnt-mass/e5b7fba5-db4e-4b9\l7-abff-53d4c078b02b\l\lobo:PATO_0000125\l",color=blue]
g12 [shape=record,label="http://dikb.org/data-rati\lo/82c59a84-b93c-4e85-866e\l-0785e827baa7\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\ldivalproex sodium-INVEGA \ldrug package auc Increase\l information\l",color=blue]
g12 -> g3 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g12 -> g44 [label="has specified value\lobo:OBI_0001937\l"]
g13 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000312\l\lrdf:Property\l",color=blue]
g14 [shape=record,label="http://purl.obolibrary.or\lg/obo/BFO_0000051\l\lrdf:Property\l",color=blue]
g15 [shape=record,label="http://dikb.org/object-dr\lug/81567612-65f5-4117-9f6\l9-cea8d180d314\l\l\<obo:RxNorm_686438\>\l|label\lrdfs:label\lINVEGA\l",color=blue]
g16 [shape=record,label="http://dikb.org/precipita\lnt-milligram/8d6ca658-608\le-4baf-8bff-219e4b2ea729\l\lobo:UO_0000022\l",color=blue]
g17 [shape=record,label="http://dikb.org/data-rati\lo-type/54518117-7137-445e\l-af1a-374688750721\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l50 Percent \l",color=blue]
g17 -> g61 [label="\lobo:OBI_0000051\l"]
g18 [shape=record,label="http://www.w3.org/1999/02\l/22-rdf-syntax-ns#type\l\lrdf:Property\l",color=blue]
g19 [shape=record,label="http://dikb.org/object-dr\lug-role/ca6fdb71-ec63-410\lf-ac0a-406709bcb125\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g20 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/5caf0caf-\l5e1d-47ba-9c15-6f24c6f642\lc8\lpercent\lobo:UO_0000187\l",color=blue]
g21 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/53cf3760-\l3f0a-45b4-9097-e86388eddf\l9d\lpercent\lobo:UO_0000187\l",color=blue]
g22 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000136\l\lrdf:Property\l",color=blue]
g23 [shape=record,label="http://dikb.org/object-dr\lug-role/7f423442-ef47-4be\l9-a1d7-1872545afa3f\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g24 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000001\l\lrdfs:Class\l",color=blue]
g25 [shape=record,label="http://dikb.org/precipita\lnt-value-specification/a1\l16271a-a01a-4b60-8df8-7e8\la72d3c8c1\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l200\l",color=blue]
g25 -> g36 [label="\lobo:IAO_0000039\l"]
g26 [shape=record,label="http://purl.obolibrary.or\lg/obo/DRON_00000028\l\lrdfs:Class\l",color=blue]
g27 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000124\l\lrdfs:Class\l",color=blue]
g28 [shape=record,label="http://dikb.org/object-va\llue-measurement-datum/1b9\l338a3-7ca6-4fb4-954e-027d\lb605d2df\l\lobo:IAO_0000109\l",color=blue]
g28 -> g49 [label="\lobo:IAO_0000221\l"]
g28 -> g72 [label="has specified value\lobo:OBI_0001937\l"]
g29 [shape=record,label="http://dikb.org/object-va\llue-measurement-datum/b8b\l8a181-db46-432a-adea-ff07\l1a3dbcd1\l\lobo:IAO_0000109\l",color=blue]
g29 -> g52 [label="\lobo:IAO_0000221\l"]
g29 -> g8 [label="has specified value\lobo:OBI_0001937\l"]
g30 [shape=record,label="http://purl.obolibrary.or\lg/obo/RO_0002351\l\lrdf:Property\l",color=blue]
g31 [shape=record,label="http://dikb.org/object-mi\llligram/e7284abb-b1ad-494\l6-be38-aede651b4447\l\lobo:UO_0000022\l",color=blue]
g32 [shape=record,label="http://dikb.org/method/ff\lfd8ecb-3541-4caf-a908-149\l6e7f63ee6\l\lobo:DIDEO_00000124\l|label\lrdfs:label\lnefazodone-digoxin DDI cl\linical trial\l",color=blue]
g33 [shape=record,label="http://dikb.org/o-scatter\led-molecular-aggregate/e0\l70aff0-ca97-468f-86b1-05d\l01071449f\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g33 -> g62 [label="\lobo:RO_0002351\l"]
g33 -> g29 [label="\lobo:RO_0000053\l"]
g33 -> g41 [label="\lobo:RO_0000053\l"]
g34 [shape=record,label="http://dikb.org/bearer-ob\lject/3e529544-1d53-482a-b\l9da-f3f4d0edb6d0\l",color=orange]
g34 -> g23 [label="\lobo:RO_0000053\l"]
g34 -> g33 [label="has part\lobo:BFO_0000051\l"]
g35 [shape=record,label="http://dikb.org/data-rati\lo/574bf84f-53e2-403e-ae0d\l-3776caa25acc\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\lnefazodone-digoxin drug p\lackage cmax Increase info\lrmation\l",color=blue]
g35 -> g59 [label="has specified value\lobo:OBI_0001937\l"]
g35 -> g32 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g36 [shape=record,label="http://dikb.org/precipita\lnt-milligram/c5e14cee-e60\lb-4e0f-903e-f9247a77d7be\l\lobo:UO_0000022\l",color=blue]
g37 [shape=record,label="http://dikb.org/bearer-pr\lecipitant/9a6ed19d-2dad-4\lf25-a032-10620bb682d6\l",color=orange]
g37 -> g43 [label="has part\lobo:BFO_0000051\l"]
g37 -> g66 [label="\lobo:RO_0000053\l"]
g38 [shape=record,label="http://dikb.org/data-rati\lo/b0f9680f-b09c-42dd-980a\l-4f66fbf35429\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\lnefazodone-digoxin drug p\lackage auc Increase infor\lmation\l",color=blue]
g38 -> g32 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g38 -> g63 [label="has specified value\lobo:OBI_0001937\l"]
g39 [shape=record,label="http://dikb.org/data-rati\lo/959cb61b-74f6-4e53-a4e2\l-00b3ccba061a\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\ldivalproex sodium-INVEGA \ldrug package cmax Increas\le information\l",color=blue]
g39 -> g3 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g39 -> g17 [label="has specified value\lobo:OBI_0001937\l"]
g40 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0001937\l\lrdf:Property\l",color=blue]
g41 [shape=record,label="http://dikb.org/object-ac\ltive-ingredient/d75bb8b8-\l25e8-4534-a1f3-8cffa3460a\ld2\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g42 [shape=record,label="http://dikb.org/precipita\lnt-active-ingredient/3042\l4846-6045-4e48-aae6-4bd8d\lfaf78ce\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g43 [shape=record,label="http://dikb.org/p-scatter\led-molecular-aggregate/70\l757561-a374-4eb9-9cb0-051\lfd5e627dd\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g43 -> g64 [label="\lobo:RO_0000053\l"]
g43 -> g0 [label="\lobo:RO_0002351\l"]
g43 -> g55 [label="\lobo:RO_0000053\l"]
g44 [shape=record,label="http://dikb.org/data-rati\lo-type/835ffb02-ff80-42b0\l-b358-a21b0058af71\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l50\l",color=blue]
g44 -> g69 [label="\lobo:OBI_0000051\l"]
g45 [shape=record,label="http://dikb.org/p-scatter\led-molecular-aggregate/e4\lbde22a-8586-403a-bd9f-bee\lc1327a101\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g45 -> g5 [label="\lobo:RO_0000053\l"]
g45 -> g48 [label="\lobo:RO_0002351\l"]
g45 -> g42 [label="\lobo:RO_0000053\l"]
g46 [shape=record,label="http://dikb.org/precipita\lnt-drug-role/aa7c58f5-9a8\l6-43f4-9d3b-34a940457b7e\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g47 [shape=record,label="http://dikb.org/assertion\l/b3a5509f-e6eb-477e-914c-\lf7a5a5fd7d59\ldrug-drug interaction des\lcription\lobo:DIDEO_00000001\l|label\lrdfs:label\ldivalproex sodium-INVEGA \linteraction description\l",color=blue]
g47 -> g12 [label="has part\lobo:BFO_0000051\l"]
g47 -> g50 [label="\lobo:IAO_0000136\l"]
g47 -> g39 [label="has part\lobo:BFO_0000051\l"]
g47 -> g58 [label="\lobo:IAO_0000136\l"]
g48 [shape=record,label="http://dikb.org/precipita\lnt-drug/c003cd94-1c9c-46e\l2-bcdb-9332842c2f9b\l\l\<obo:MeSH_D014635\>\l|label\lrdfs:label\ldivalproex sodium\l",color=blue]
g49 [shape=record,label="http://dikb.org/object-ma\lss/aa1cd42c-b063-4c11-827\l0-33d6452b5312\l\lobo:PATO_0000125\l",color=blue]
g50 [shape=record,label="http://dikb.org/bearer-pr\lecipitant/3001eecf-c065-4\le59-ab90-03437a4e438c\l",color=orange]
g50 -> g46 [label="\lobo:RO_0000053\l"]
g50 -> g45 [label="has part\lobo:BFO_0000051\l"]
g51 [shape=record,label="http://www.w3.org/2000/01\l/rdf-schema#label\l\lrdf:Property\l",color=blue]
g52 [shape=record,label="http://dikb.org/object-ma\lss/91e39034-b50b-4284-94d\l3-c2da81e8b312\l\lobo:PATO_0000125\l",color=blue]
g53 [shape=record,label="http://dikb.org/assertion\l/ee1a519b-46c2-4c50-8dbe-\l5955b5091532\ldrug-drug interaction des\lcription\lobo:DIDEO_00000001\l|label\lrdfs:label\lnefazodone-digoxin intera\lction description\l",color=blue]
g53 -> g34 [label="\lobo:IAO_0000136\l"]
g53 -> g38 [label="has part\lobo:BFO_0000051\l"]
g53 -> g37 [label="\lobo:IAO_0000136\l"]
g53 -> g35 [label="has part\lobo:BFO_0000051\l"]
g54 [shape=record,label="http://dikb.org/object-ac\ltive-ingredient/b3aafeca-\l7844-46e5-966a-caa264f340\l14\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g55 [shape=record,label="http://dikb.org/precipita\lnt-active-ingredient/17c4\l6710-e53c-4058-aa1d-7810b\l2442351\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g56 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000051\l\lrdf:Property\l",color=blue]
g57 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0001933\l\lrdfs:Class\l",color=blue]
g58 [shape=record,label="http://dikb.org/bearer-ob\lject/212ac19a-d895-4c6d-9\l219-004184024d4c\l",color=orange]
g58 -> g70 [label="has part\lobo:BFO_0000051\l"]
g58 -> g19 [label="\lobo:RO_0000053\l"]
g59 [shape=record,label="http://dikb.org/data-rati\lo-type/6281350e-d055-431d\l-9dd2-9a49be4b4dce\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l29 Percent \l",color=blue]
g59 -> g21 [label="\lobo:OBI_0000051\l"]
g60 [shape=record,label="http://dikb.org/object-mi\llligram/2983d993-2335-4b3\l4-8bdf-330af88ec141\l\lobo:UO_0000022\l",color=blue]
g61 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/ed10e1c5-\l7c9c-49b5-b727-f13f334f47\lb3\lpercent\lobo:UO_0000187\l",color=blue]
g62 [shape=record,label="http://dikb.org/object-dr\lug/55888d8a-af45-48aa-b57\l4-f679f2318427\l\l\<obo:RxNorm_3407\>\l|label\lrdfs:label\ldigoxin\l",color=blue]
g63 [shape=record,label="http://dikb.org/data-rati\lo-type/3275118b-fb34-44a0\l-8e39-4f584cb4b5ea\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l15\l",color=blue]
g63 -> g20 [label="\lobo:OBI_0000051\l"]
g64 [shape=record,label="http://dikb.org/precipita\lnt-value-measurement-datu\lm/db62eea3-6725-45ae-b3ea\l-f3d8ede9760f\l\lobo:IAO_0000109\l",color=blue]
g64 -> g25 [label="has specified value\lobo:OBI_0001937\l"]
g64 -> g11 [label="\lobo:IAO_0000221\l"]
g65 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000013\l\lrdfs:Class\l",color=blue]
g66 [shape=record,label="http://dikb.org/precipita\lnt-drug-role/09cb66a2-76f\ld-44dc-b757-49743f378121\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g67 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000221\l\lrdf:Property\l",color=blue]
g68 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000050\l\lrdfs:Class\l",color=blue]
g69 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/8a18ddbf-\l8a7b-4aa1-834b-8e4f07add2\l97\lpercent\lobo:UO_0000187\l",color=blue]
g70 [shape=record,label="http://dikb.org/o-scatter\led-molecular-aggregate/bb\l9944b7-794b-4011-ae25-b5f\l5f1f44604\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g70 -> g28 [label="\lobo:RO_0000053\l"]
g70 -> g15 [label="\lobo:RO_0002351\l"]
g70 -> g54 [label="\lobo:RO_0000053\l"]
g71 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000109\l\lrdfs:Class\l",color=blue]
g72 [shape=record,label="http://dikb.org/object-va\llue-specification/726bb02\l0-6721-4cb7-bde5-7b787e87\l543f\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l12\l",color=blue]
g72 -> g60 [label="\lobo:IAO_0000039\l"]
g73 [shape=record,label="http://dikb.org/precipita\lnt-value-specification/12\l44642e-8693-4102-926b-076\lc67f4994e\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l1000\l",color=blue]
g73 -> g16 [label="\lobo:IAO_0000039\l"]
}